Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies | Zendy

Joseph J. Eron | Zendy; ChienChing Hung | Zendy; JeanGuy Baril | Zendy; Jihad Slim | Zendy; Vicenç Falcó | Zendy; Johannes R. Bogner | Zendy; Franco Maggiolo | Zendy; Anthony Mills | Zendy; Jörg Sievers | Zendy; Choy Man | Zendy; Alexander Currie | Zendy; Mark Underwood | Zendy; Allan R. Tenorio | Zendy; Keith A. Pappa | Zendy; Brian Wynne | Zendy; Justin Koteff | Zendy; Martin Gartland | Zendy; Kimberly Y. Smith | Zendy; Michael Aboud | Zendy; Alistair G. Paice | Zendy

Open Access

Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies

Author(s) -

Joseph J. Eron,

ChienChing Hung,

JeanGuy Baril,

Jihad Slim,

Vicenç Falcó,

Johannes R. Bogner,

Franco Maggiolo,

Anthony Mills,

Jörg Sievers,

Choy Man,

Alexander Currie,

Mark Underwood,

Allan R. Tenorio,

Keith A. Pappa,

Brian Wynne,

Justin Koteff,

Martin Gartland,

Kimberly Y. Smith,

Michael Aboud,

Alistair G. Paice

Publication year - 2019

Publication title -

journal of infection and public health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.983

H-Index - 35

eISSN - 1876-035X

pISSN - 1876-0341

DOI - 10.1016/j.jiph.2019.02.003

Subject(s) - dolutegravir , emtricitabine , tenofovir , lamivudine , medicine , viral load , virology , antiretroviral therapy , human immunodeficiency virus (hiv) , virus , hepatitis b virus

1University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA; 2National Taiwan University Hospital, Taipei, Taiwan; 3Clinique Médicale du Quartier Latin, Montréal, Québec, Canada; 4Saint Michael’s Medical Center, Newark, NJ, USA; 5Hospital Vall d'Hebron, Barcelona, Spain; 6Klinikum der Universität München, Munich, Germany; 7ASST Papa Giovanni XXIII, Bergamo, Italy; 8Men’s Health Foundation, Los Angeles CA, USA; 9ViiV Healthcare, Brentford, UK; 10ViiV Healthcare, Research Triangle Park, NC, USA; 11GlaxoSmithKline, Stockley Park, UK Initial Viral Load Decline and Response Rates by Baseline Viral Load Strata With Dolutegravir Plus Lamivudine Versus Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Results From the GEMINI Studies

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research